- You are here:
- Home
- > Local NHS Services
- > Individual Funding Requests (IFR)
- > Y&H Specialised Commissioning Group
Treatments not routinely available from your local NHS
(Individual Funding Requests)
Yorkshire and the Humber Specialised Commissioning Group: General Policies
Yorkshire and The Humber Specialised Commissioning Group (SCG) produces and implements, on behalf of the 14 member PCTs, commissioning policies with respect to specialised services. These are services which are part of a national definition set of specialist services.
A list of current approved commissioning policies is given below. Additional policies may be found on the Yorkshire and Humber SCG website.
When making decisions on exceptional requests for funding, NHS Sheffield refers to the following general polices where appropriate
- Documents:
- Alemtuzumab for B-cell chronic lymphocytic leukaemia (11kb pdf)
- Armour thyroid for Hypothyroidism (53kb pdf)
- Azacitidine for intermediate -2 and high-risk MDS / CMML with 10 - 29 % marrow blasts without myeloproliferative disorder / AML with 20 - 30 % blasts and multi-lineage dysplasia (11kb pdf)
- Bevacizumab for Glioblastoma (10kb pdf)
- Bevacizumab for Metastatic breast cancer (11kb pdf)
- Bevacizumab for Metastatic Colorectal Cancer (30kb pdf)
- Bevacizumab (IV) for Metastatic Breast Cancer policy (26kb pdf)
- Bevacizumab / Sorafenib / Sunitinib / Temsirolimus for renal cell cancer (NICE) (103kb pdf)
- Bortezomib for Multiple myeloma (1st-line) (11kb pdf)
- Botulinum toxin type A for Hyperhidrosis (excessive sweating) (70kb pdf)
- Botulinum toxin A for Overactive bladder (Unlicensed indication) (67kb pdf)
- Botulinum toxin type A for Prophylaxis of migraine – unlicensed indication (31kb pdf)
- Botulinum toxin A for treatment of anal fissures (unlicensed indication) (46kb pdf)
- Capecitabine for Gastric cancer (29kb pdf)
- Cetuximab 1st line for colorectal cancer (NICE) (116kb pdf)
- Cetuximab for 2nd line and subsequent metastatic colorectal cancer in patient with K-ras wild-type tumours (32kb pdf)
- Cetuximab 3rd line for wild type KRAS colorectal cancer (iEDM) (119kb pdf)
- Cetuximab for Head and neck cancer (squamous cell carcinoma) (80kb pdf)
- Clofarabine for Acute lymphoblastic leukaemia (11kb pdf)
- Co-careldopa 2000mg/500mg intestinal gel for administration via PEG tube for treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results (48kb pdf)
- Dasatinib for Acute lymphoblastic leukaemia; chronic myeloid leukaemia (11kb pdf)
- Delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray for Symptoms associated with multiple sclerosis, including spasticity and pain (26kb pdf)
- Docetaxel for Induction treatment of patients with locally advanced inoperable squamous cell carcinoma of the head and neck (25kb pdf)
- Erlotinib for Non-small cell lung cancer (3rd line) (11kb pdf)
- Everolimus (Oral) for Advanced and/or metastatic renal cell carcinoma policy (49kb pdf)
- Fertility - Commissioning policy Specialised Fertility Services (302kb pdf)
- Gefitinib (oral) for Locally advanced or metastatic non-small cell lung cancer (NSCLC) (40kb pdf)
- Gemcitabine IV infusion & Capecitabine 150mg or 500mg tablets (37kb pdf)
- Imatinib for Acute lymphoblastic leukaemia (11kb pdf)
- Imatinib for Gastrointestinal stromal tumours (GIST) (38kb pdf)
- Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on NICE TA 86) (12kb pdf)
- Infliximab for Hidradenitis Suppurtiva (62kb pdf)
- Interferon beta-1b for Multiple sclerosis (25kb pdf)
- Interim Cancer Drugs Fund (ICDF) Policy (282kb pdf)
- Interim Cancer Drugs Fund (ICDF) Priority Medicines List (38kb pdf)
- Lapatinib for Breast cancer (11kb pdf)
- Lenalidomide for Multiple myeloma (89kb pdf)
- Mecasermin for Growth Failure in children and adolescents (47kb pdf)
- Ofatumumab for chronic lymphocytic leukaemia (11kb pdf)
- Paclitaxel for Ovarian cancer, breast cancer, lung cancer policy (41kb pdf)
- Palivizumab for RSV prophylaxis (regional expert panel) (122kb pdf)
- Pemetrexed 1st line for NSCLC (NICE) (91kb pdf)
- Pemetrexed for Non-small cell lung cancer (2nd line) (11kb pdf)
- Penile prostheses for Erectile Dysfunction (50kb pdf)
- Rituximab (alone or with DMARD other than methotrexate) for RA (iEDM) (796kb pdf)
- Rituximab for chronic lymphocytic leukaemia (NICE) (96kb pdf)
- Rituximab for Follicular lymphoma (1st line maintenance) (11kb pdf)
- Rituximab for SLE in adults (unlicensed) (73kb pdf)
- Rituximab for Relapsed or refractory chronic lymphocytic leukaemia (CLL) (40kb pdf)
- Sacral Nerve Stimulation [SNS] (Sacral Nerve Neuromodulation) (68kb pdf)
- Specialist Plastic Surgery Procedures (227kb pdf)
- Spinal Cord Stimulation (neuromodulation) for Intractable Chronic Pain (of neuropathic or ischaemic origin) (kb pdf)
- Sunitinib for Advanced pancreatic neuroendocrine tumours (NET) (11kb pdf)
- Sunitinib for GIST (NICE) (92kb pdf)
- Thalidomide for Multiple myeloma policy (253kb pdf)
- Topotecan for Cervical cancer (in patients having received cisplatin > 12 months previously) (11kb pdf)
- Trabectedin for Advanced soft tissue sarcoma (27kb pdf)
- Trastuzumab for gastric cancer (HR2-positive metastatic) (23kb pdf)
(files are pdf and wil open in a new window)
Individual Funding Requests main page
- Share this!
- Delicious
- Digg
- StumbleUpon
